The Weekly Summary

April 22nd – April 28th                                 2019

In general news, North Korea’s Kim Jong un traveled to Moscow to meet with Putin. President Trump pledged to arm border guards after video made the news of armed Mexican soldiers escorting illegals over the border. Trump also summoned Twitter CEO Jack Dorsey into the Oval Office to complain about censorship of conservative sites (which is a far greater meddling in the election process than anything Russia ever did). In politics, Creepy Joe Biden officially entered the race for 2020. In the economy, stocks hit all-time highs and the Q1 GDP was 3.2%, blowing away expectations as earnings from companies beat as well. The economy is on fire.

In healthcare news, the measles epidemic spread. UCLA and Cal quarantined students. Half of schizophrenia cases are misdiagnosed. The patients really had just anxiety or other lesser ailments. Also, President Trump went to Atlanta for an opioid crisis summit.

In healthcare business news, earnings season continued with more companies beating estimates. However, Edwards (EW) missed again on poor TAVR. Lilly (LLY) plans to spin off legacy drugs to China. The DOJ is reviewing the patents held by Gilead (GILD) for HIV drugs Truvada since they are price gouging, and CMS Director Verma denounced Bernie Sanders’ Medicare-for-all.

On the data front, a group of scientists called for a global ban on CRISPR editing of human embryos. A Novartis (NVS) gene trial reported a second death. Also, Lilly (LLY) reported positive data on Taltz to treat non-radiographic axial spondyloarthritis.

From the FDA, Teva’s (TEVA) generic naloxone was approved to compete with Emergent BioSolutions’ (EBS) Narcan. AbbVie (ABBV) received approval for Skyrizo to treat psoriasis as its own Humira goes off patent. Finally, an electrical shocking device, Monarch eTNS System made by private NeuroSigma, to treat ADHD in kids, avoiding medication, was approved.

This entry was posted in - The Weekly Summary. Bookmark the permalink.